Table 4.
Lead author | Neonatal HSV infection | Genital herpes | |||||||
---|---|---|---|---|---|---|---|---|---|
Neonatal perspective | Maternal perspective | ||||||||
HSUV | Duration (years) | Probability of health state | HSUV | Duration (years) | Probability of health state | HSUV | Duration (years) | Probability of health state | |
Baker [17] | No permanent impairment: 1 | 76.4 | 0.56 | ||||||
Mild: 0.82 | 76.4 | 0.05 | ·· | ·· | ·· | ·· | ·· | ·· | |
Moderate: 0.52 | 76.4 | 0.08 | ·· | ·· | ·· | ·· | ·· | ·· | |
Severe: 0.16 | 20 | 0.14 | ·· | ·· | ·· | ·· | ·· | ·· | |
Death: 0 | . | 0.17 | ·· | ·· | ·· | ·· | ·· | ·· | |
Caviness [18] | Normal: 1 | 77.8 | ·· | ·· | ·· | ·· | ·· | ·· | ·· |
Mild: 0.82 | 77.8 | Differs according to treatment arm, time and disease state (e.g., 12-month outcome with acyclovir therapy for disseminated disease: Normal: 0.28, Mild: 0.04, Moderate: 0.02, Severe: 0.13, Death: 0.53) | ·· | ·· | ·· | ·· | ·· | ·· | |
Moderate: 0.52 | 77.8 | ·· | ·· | ·· | ·· | ·· | ·· | ||
Severe: 0.16 | 20 | ·· | ·· | ·· | ·· | ·· | ·· | ||
Death: 0 | . | ·· | ·· | ·· | ·· | ·· | ·· | ||
Chatroux [4] | Mild: 0.82 | 79.3 | HSV-1: 0.69; HSV-2: 0.49 | Mild: 0.94 | 54.8 | HSV-1: 0.69; HSV-2: 0.49 | ·· | ·· | ·· |
Moderate: 0.52 | 79.3 | HSV-1: 0.01; HSV-2: 0.14 | Moderate: 0.87 | 54.8 | HSV-1: 0.01; HSV-2: 0.14 | ·· | ·· | ·· | |
Severe: 0.16 | 20 | HSV-1: 0.02; HSV-2: 0.17 | Severe: 0.76 | 54.8 | HSV-1: 0.02; HSV-2: 0.17 | ·· | ·· | ·· | |
Death: 0 | ·· | HSV-1: 0.28; HSV-2: 0.2 | Death: 0.92 | 54.8 | HSV-1: 0.28; HSV-2: 0.2 | ·· | ·· | ·· | |
Little [19] | Normal neonate: 1 | 77.2 | # | Caesarean delivery: 0.99 | 55.4 | If lesions present at delivery: 1; if no lesions present: 0.244 | ·· | ·· | ·· |
Moderate: 0.9 | 62.0 | HSV-1: 0.01, HSV-2: 0.14 | Having an impaired child: 0.81 | 55.4 | Not reported | ·· | ·· | ·· | |
Severe: 0.3 | 28.7 | HSV-1: 0.01, HSV-2: 0.17 | Losing a child: 0.92 | 55.4 | Not reported | ·· | ·· | ·· | |
Death: 0 | ·· | HSV-1: 0.28, HSV-2: 0.20 | ·· | ·· | ·· | ·· | ·· | ·· | |
Smith [20] | ·· | ·· | ·· | ·· | ·· | ·· | Stigma: 0.95 | 10 | Unclear |
·· | ·· | ·· | ·· | ·· | ·· | Symptomatic recurrence: 0.90 | 10 | ||
Tuite [16] | Normal/mild: 1 | 75 | Unclear | ·· | ·· | ·· | ·· | ·· | ·· |
Moderate: 0.84 | 38 | Unclear | ·· | ·· | ·· | ·· | ·· | ·· | |
Severe: 0.41 | 38 | Unclear | ·· | ·· | ·· | ·· | ·· | ·· | |
Death: 0 | ·· | Unclear | ·· | ·· | ·· | ·· | ·· | ·· | |
Thung [21] | Normal: 1 | 76 | Unclear | ·· | ·· | ·· | ·· | ·· | ·· |
Mild: 1 | 76 | Unclear | ·· | ·· | ·· | ·· | ·· | ·· | |
Moderate: 0.5 | 76 | Unclear | ·· | ·· | ·· | ·· | ·· | ·· | |
Severe: 0.1 | 76 | Unclear | ·· | ·· | ·· | ·· | ·· | ·· | |
Death: 0 | . | Unclear | ·· | ·· | ·· | ·· | ·· | ·· |
HSUV health-state utility values; HSV Herpes simplex virus; QALY quality-adjusted life years